Endocrine Abstracts

Background: It is known that the prevalence of skin diseases in patients with type 2 diabetes (T2D) is increased including psoriasis. Patients with T2D and psoriasis have an increased risk of psoriasis exacerbations. The study of the psoriasis manifestation features in patients with T2D can help to reduce the number of exacerbations, their severity and duration.

Aims: To study the influence of T2D on the psoriasis manifestation and exacerbation. Materials and Methods We studied hospitalized patients with T2D and psoriasis in dermatological clinic during 5 years (n = 47) - the main group. Comparison group 1- patients with psoriasis without T2D (n = 40), comparison group 2 - patients with T2D without psoriasis (n = 37). Patients were excluded: with the psoriatic arthritis, GFR≤45 ml/min/1.73 m².

Results: Patients of the main group (women-53.2%, men-46.8%, mean age 61.0±7.7 years), comparison group 1 (women-55%, men- 45%, mean age 60.5±7.5 years), comparison group 2 (women-54%, men-46%, mean age 62.0±7.8 years) were same in clinical, anthropometric, anamnestic and laboratory data (AST, ALT, total cholesterol, creatinine, P > 0,05). Patients of the main group and comparison group 1 differed in serum glycaemia (P = 0.005), HbA1c (P = 0.009). Patients of the main group had an increase HbA1c (11.8 (7.9-12.3)) compared with the comparison group 2 (6.8(6.1-7.3), P = 0.006) in the exacerbation of psoriasis period. All patients of the main group were ranked into groups depending on the HbA1c level. HbA1c<7.0% was detected in 8.5% (n = 4) of patients with T2D and psoriasis, HbA1c 7.0-8.5% -in 31.9% (n = 15), HbA1c>8.5% - in 59.6% (n = 28) cases. Thus, result of the study indicates a decrease in glycemic control in 91.5% patients of the main group for a period of at least 3 months before the psoriasis exacerbation. DiscussionResult of the study indicates a decrease in glycemic control in patients with T2D and psoriasis before the psoriasis exacerbation. There is probably a correlation between psoriasis exacerbation and low glycemic control in patients with T2D and psoriasis.